Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Trump Media and Technology Group Corp (DJT) vs Novavax Inc (NVAX) Price & Performance

Trump Media and Technology Group CorpTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Trump Media and Technology Group Corp vs Novavax Inc — how do they compare? Trump Media and Technology Group Corp trades at $8.35 (market cap $2.48B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Trump Media and Technology Group Corp is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.

DJTNVAX
Market Cap
$2.48B$1.31B
Sector
MediaHealth
52-Week High
$18.50$11.19
52-Week Low
$7.06$6.22
Enterprise Value
$2.54B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Trump Media and Technology Group Corp

DJT stock trades at $8.27, down 11.93% in the last session, reflecting bearish technical signals and fundamental challenges. The company reported Q2 2026 revenue of $1.67 million with a net loss of $238.1 million, driven by digital asset declines. Technical indicators show strong bearish momentum with support at $8 and resistance at $9-10 levels.

Outlook remains challenging with unsustainable valuation metrics (P/S ratio of 547.62) and persistent cash burn. Investment opportunities are limited given negative profitability and high business execution risks. Key risks include continued losses, competitive pressures, and volatile digital asset holdings affecting financial results.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Trump Media and Technology Group Corp

Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.

Read more on DJT

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX